Trexquant Investment LP Lowers Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)

Trexquant Investment LP lessened its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 50.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,343 shares of the company's stock after selling 11,506 shares during the period. Trexquant Investment LP owned approximately 0.06% of USANA Health Sciences worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Barclays PLC raised its position in shares of USANA Health Sciences by 111.9% in the third quarter. Barclays PLC now owns 27,737 shares of the company's stock worth $1,052,000 after acquiring an additional 14,647 shares during the period. Pzena Investment Management LLC raised its holdings in USANA Health Sciences by 3.6% in the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after purchasing an additional 37,466 shares during the period. Principal Financial Group Inc. boosted its position in USANA Health Sciences by 2.8% during the fourth quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock worth $1,924,000 after purchasing an additional 1,480 shares in the last quarter. Rhumbline Advisers grew its holdings in USANA Health Sciences by 39.8% in the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock valued at $1,773,000 after purchasing an additional 14,068 shares during the period. Finally, Norges Bank purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at approximately $953,000. Hedge funds and other institutional investors own 54.25% of the company's stock.

Insider Transactions at USANA Health Sciences

In related news, insider Joshua Foukas sold 5,732 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares in the company, valued at $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock worth $500,285 over the last ninety days. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on USNA. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. Finally, DA Davidson reduced their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th.

USANA Health Sciences Stock Up 1.3 %

NYSE:USNA traded up $0.32 during mid-day trading on Friday, reaching $23.75. 261,409 shares of the stock were exchanged, compared to its average volume of 118,179. The stock has a market capitalization of $448.90 million, a P/E ratio of 8.39, a P/E/G ratio of 0.93 and a beta of 1.00. USANA Health Sciences, Inc. has a 1 year low of $23.26 and a 1 year high of $49.78. The company has a 50 day simple moving average of $28.59 and a 200-day simple moving average of $33.66.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. As a group, research analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.